Stalevo, a combo product for Parkinson's disease

See FDA information concerning a possible increased cardiovascular risk with Stalevo

Novartis is now marketing Stalevo, a combo product for Parkinson's disease.

It contains both standard-release carbidopa/levodopa (Sinemet, etc)...PLUS entacapone (Comtan).

It's for patients who already take these drugs separately... or for patients who have "wearing-off" on levodopa. Adding entacapone boosts efficacy of levodopa and helps it last longer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote